Pharma industry venture financing deals in Q1 2019 total $4.93bn globally

Total pharma industry venture financing deals in Q1 2019 worth $4.93bn were announced globally, according to GlobalData’s deals database.

The value marked a decrease of 3.5% over the previous quarter and a drop of 8.8% when compared with the last four-quarter average, which stood at $5.42bn.

Comparing deals value in different regions of the globe, North America held the top position, with total announced deals in the period worth $3.37bn. At the country level, the US topped the list in terms of deal value at $3.37bn.

In terms of volumes, North America emerged as the top region for pharma industry venture financing deals globally, followed by Europe and then Asia-Pacific.

The top country in terms of venture financing deals activity in Q1 2019 was the US with 163 deals, followed by China with 23 and Switzerland with 11.

In 2019, as of the end of Q1 2019, pharma venture financing deals worth $4.93bn were announced globally, marking a decrease of 13.8% year on year.

Pharma industry venture financing deals in Q1 2019: Top deals

The top five pharma industry venture financing deals accounted for 19.4% of the overall value during Q1 2019.

The combined value of the top five pharma industry venture financing deals stood at $955.06m, against the overall value of $4.93bn recorded for the quarter. The top announced pharma industry venture financing deal tracked by GlobalData in Q1 2019 was Aisling Capital, American International Group, Cormorant Capital, Hercules Capital, Kohlberg Kravis Roberts & Co, Perceptive Advisors, Sequoia Capital Operations and Viking Global Investors’ $299.2m venture financing of BridgeBio Pharma.

In second place was the $191m venture financing of Maze Therapeutics by Alexandria Venture Investments, ARCH Venture Partners, Casdin Capital, Foresite Capital Management, GV Management Co and Third Rock Ventures and in third place was BRV Capital Management, Andera Partners, H.I.G. BioHealth Partners, Life Sciences Partners and NovaQuest Capital Management’s $179.86m venture financing of Arvelle Therapeutics.

The $150m venture financing of Peloton Therapeutics by Biotechnology Value Fund, Curative Ventures, Driehaus Capital Management, EcoR1 Capital, Eventide Asset Management, Foresite Capital Management, Nextech Invest, Orbimed Advisors, RA Capital Management, The Column Group, Tichenor Ventures, Topspin Fund and Vida Ventures and Altitude Life Science Ventures, ARCH Venture Partners, Cormorant Asset Management, Eight Roads Ventures, F-Prime, Omega Fund Management and Redmile Group’s venture financing of Beam Therapeutics for $135m held fourth and fifth positions, respectively.

This analysis considers only announced and completed deals from the GlobalData financial deals database and excludes all terminated and rumoured deals. Country and industry are defined according to the headquarters and dominant industry of the target firm. The term ‘acquisition’ refers to both completed deals and those in the bidding stage.

GlobalData tracks real-time data concerning all merger and acquisition, private equity/venture capital and asset transaction activity around the world from thousands of company websites and other reliable sources.

More in-depth reports and analysis on all reported deals are available for subscribers to GlobalData’s deals database.